290 related articles for article (PubMed ID: 8643093)
1. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
3. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
Evans CH; Baker PD
Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622
[TBL] [Abstract][Full Text] [Related]
4. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
5. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
6. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
9. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
Côme MG; Skladanowski A; Larsen AK; Laurent G
Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
[TBL] [Abstract][Full Text] [Related]
10. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
11. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
13. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
14. [Anthracycline transport in sensitive and resistant leukemia cells].
Erttmann R; Erb N; Forcadell de Dios P; Neurath C; Looft G; Landbeck G
Klin Padiatr; 1989; 201(1):40-5. PubMed ID: 2704176
[TBL] [Abstract][Full Text] [Related]
15. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.
Keizer HG; Schuurhuis GJ; Broxterman HJ; Lankelma J; Schoonen WG; van Rijn J; Pinedo HM; Joenje H
Cancer Res; 1989 Jun; 49(11):2988-93. PubMed ID: 2566376
[TBL] [Abstract][Full Text] [Related]
16. The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells.
Głowacka-Rogacka D; Arciemiuk M; Kupiec A; Bontemps-Gracz MM; Borowski E; Tarasiuk J
Cancer Detect Prev; 2004; 28(4):283-93. PubMed ID: 15350632
[TBL] [Abstract][Full Text] [Related]
17. The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells.
Tarasiuk J; Majewska E; Seksek O; Rogacka D; Antonini I; Garnier-Suillerot A; Borowski E
Biochem Pharmacol; 2004 Nov; 68(9):1815-23. PubMed ID: 15450947
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
Molnár J; Hevér A; Fakla I; Fischer J; Ocsovski I; Aszalós A
Anticancer Res; 1997; 17(1A):481-6. PubMed ID: 9066699
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer.
Alakhov VYu ; Moskaleva EYu ; Batrakova EV; Kabanov AV
Bioconjug Chem; 1996; 7(2):209-16. PubMed ID: 8983343
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
